High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
补充高剂量维生素 D 治疗老年前列腺癌患者 ADT 引起的骨质流失
基本信息
- 批准号:10542392
- 负责人:
- 金额:$ 62.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-12-17 至 2026-11-30
- 项目状态:未结题
- 来源:
- 关键词:AgeAgonistAlcoholsAmerican Society of Clinical OncologyBiologicalBiological MarkersBone DensityCalciumCancer CenterCancer PatientCancer SurvivorCholecalciferolClinicalClinical Practice GuidelineCommunity Clinical Oncology ProgramCountryDataDistalDoseDouble-Blind MethodDual-Energy X-Ray AbsorptiometryElderlyEnsureEquilibriumExerciseFemurFractureGNRH1 geneHigh PrevalenceHip FracturesHip region structureHypercalcemiaIncidenceInterventionIntervention TrialInvestigationMalignant NeoplasmsMalignant neoplasm of prostateMeasuresMetastatic Prostate CancerMorbidity - disease rateMuscleMuscular AtrophyNeckNonmetastaticOncologistOsteoporosisOutcomeParticipantPathway interactionsPatientsPeptide Initiation FactorsPhasePilot ProjectsPlacebosPopulationPreparationPreventionPreventive treatmentProstate Cancer therapyPublishingQuality of lifeRadialRandomizedRandomized, Controlled TrialsRecommendationRegimenResearchSafetySerumSiteSkeletal MuscleSmokingSupplementationTestosteroneToxic effectUniversitiesVertebral columnVitamin DVitamin D supplementationandrogen deprivation therapyantagonistarmbisphosphonatebonebone cellbone healthbone lossclinical practiceclinically relevantcommunity settingcostdesignefficacy testingfallsfracture riskhigh riskhigh risk populationhip bonehuman old age (65+)improvedmachine learning methodmenmortalitymuscle formmuscle strengthnovelolder patientpharmacologicplacebo grouppreventprimary outcomeprogramsresponsesarcopeniasecondary outcomeside effect
项目摘要
ABSTRACT:
Use of androgen deprivation therapy (ADT), which causes near-total loss of testosterone, has increased
dramatically in elderly prostate cancer patients over the last decade. ADT is associated with a significant increase
in bone mineral density (BMD) loss (2-5% annually) and bone fractures, combined with a significant decrease in
skeletal muscle mass (2-5% annually) compared to age-matched prostate cancer patients not on ADT and men
without cancer. The loss of BMD and muscle mass results in a high prevalence of falls, reduced muscular
strength, and decreased balance. Despite the high incidence of ADT-related side effects, treatment options are
limited. Bisphosphonate therapy is commonly used for ADT-induced bone loss, but is associated with significant
side effects and poor compliance. Vitamin D protects against BMD loss and fractures, but its effects are strongly
dose-dependent. Current IOM recommended supplementation (600-800 IU/day) and serum 25-OH levels (20
ng/mL) are inadequate to protect against bone loss in a high risk population such as prostate cancer patients on
ADT. In addition, RCT interventions of 400-500 IU/day of vitamin D fail to prevent ADT-induced bone loss. High-
dose vitamin D supplementation (e.g., 50,000 IU/week) is a promising intervention that significantly increases
25-OH vitamin D to levels shown to improve BMD in other populations. Vitamin D has also been shown to
increase muscular strength, reduce falls, and improve balance. In preparation for this R01, we conducted a
Phase II randomized controlled trial (RCT) investigating the feasibility, safety, and preliminary efficacy of HDVD
versus placebo for 24 weeks in 59 prostate cancer patients receiving ADT (NCI R21CA185678; PI: Peppone).
Compelling evidence from our pilot study showed: 1) 50,000 IU/week of vitamin D (HDVD) was safe with no
increase in toxicity versus low-dose vitamin D, 2) compliance was excellent at 94%, and 3) HDVD significantly
increased 25-OH vitamin D levels. Those randomized to HDVD lost 1.9% BMD at the total hip versus 3.7% loss
in the placebo group (p=0.03). Stratified analyses showed the HDVD group lost 2.3% BMD at the total hip vs
7.1% for the placebo group for those with baseline vitamin D <27 ng/ml (p<0.01). Based on our preliminary data,
we propose to conduct a definitive, multi-center, phase III RCT in which 366 prostate cancer patients ≥65 years
old starting ADT with vitamin D <27 ng/ml will be randomized to 1) 50,000 IU/week vitamin D or 2) a matching
placebo for 52 weeks. All participants will receive a daily supplementation (800 IU vitamin D/1,000 mg calcium)
to ensure a minimum of 100% RDA. The primary outcomes is the change in BMD, while secondary outcomes
include changes in the clinically relevant outcomes of falls, balance, quality of life and fractures. We also plan to
explore the biological pathways of ADT-induced bone loss and response to HDVD using bone biomarkers. If
found to be efficacious, HDVD would be a safe, low-cost, widely-available OTC treatment that could revolutionize
management of ADT-induced bone loss and change clinical practice paradigms.
摘要:
雄激素剥夺疗法(ADT)的使用,导致睾丸激素几乎完全丧失,
在过去的十年里,老年前列腺癌患者中发生了显着变化。ADT与显著增加
骨矿物质密度(BMD)损失(每年2-5%)和骨折,结合显着减少,
与年龄匹配的未接受ADT的前列腺癌患者和男性相比,骨骼肌质量(每年2-5%)
没有癌症骨密度和肌肉质量的损失导致福尔斯、肌肉萎缩和肌肉萎缩的高患病率。
力量和平衡下降。尽管ADT相关副作用的发生率很高,但治疗选择
有限公司双膦酸盐治疗通常用于ADT诱导的骨丢失,但与显著的
副作用和依从性差。维生素D可以防止骨密度损失和骨折,但其作用是强烈的。
剂量依赖性。目前IOM推荐的补充剂(600-800 IU/天)和血清25-OH水平(20
ng/mL)不足以防止高风险人群(如前列腺癌患者)的骨丢失,
ADT。此外,400-500 IU/天维生素D的RCT干预未能预防ADT诱导的骨丢失。高-
补充维生素D的剂量(例如,50,000 IU/周)是一种有希望的干预措施,
25-OH维生素D的水平显示,以改善其他人群的BMD。维生素D也被证明
增加肌肉力量,减少福尔斯,改善平衡。为了准备这次R 01,我们进行了一次
研究HDVD可行性、安全性和初步疗效的II期随机对照试验(RCT)
与安慰剂相比,在59名接受ADT的前列腺癌患者中进行了24周的研究(NCI R21 CA 185678; PI:Peptide)。
我们的初步研究的令人信服的证据表明:1)50,000 IU/周的维生素D(HDVD)是安全的,
与低剂量维生素D相比,毒性增加,2)依从性极好,为94%,3)HDVD显著
增加25-OH维生素D水平。随机分配至HDVD的患者全髋关节骨密度下降1.9%,而对照组下降3.7%
安慰剂组(p=0.03)。分层分析显示,HDVD组全髋BMD损失2.3%,
对于基线维生素D <27 ng/ml的患者,安慰剂组为7.1%(p<0.01)。根据我们的初步数据,
我们计划进行一项确定性的、多中心的III期随机对照试验,纳入366例年龄≥65岁的前列腺癌患者,
维生素D <27 ng/ml的老年起始ADT将随机分配至1)50,000 IU/周维生素D或2)匹配的
安慰剂52周。所有参与者将接受每日补充(800 IU维生素D/1,000 mg钙)
确保最低100% RDA。主要结局是BMD的变化,而次要结局
包括福尔斯、平衡、生活质量和骨折的临床相关结局的变化。我们还计划
探索ADT诱导的骨丢失的生物学途径和使用骨生物标志物对HDVD的反应。如果
HDVD被发现有效,将成为一种安全、低成本、广泛使用的OTC治疗方法,可能会带来革命性的变化
管理ADT引起的骨丢失和改变临床实践模式。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Luke Joseph Peppone其他文献
Luke Joseph Peppone的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Luke Joseph Peppone', 18)}}的其他基金
High-dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
补充高剂量维生素 D 治疗老年前列腺癌患者 ADT 引起的骨质流失
- 批准号:
10374552 - 财政年份:2021
- 资助金额:
$ 62.6万 - 项目类别:
High-dose Vitamin D Supplementation for ADT-induced Side Effects
补充高剂量维生素 D 治疗 ADT 引起的副作用
- 批准号:
8637300 - 财政年份:2014
- 资助金额:
$ 62.6万 - 项目类别:
Feasibility of Omega-3 Supplementation for Cancer-related Fatigue
补充 Omega-3 治疗癌症相关疲劳的可行性
- 批准号:
8817262 - 财政年份:2014
- 资助金额:
$ 62.6万 - 项目类别:
Feasibility of Omega-3 Supplementation for Cancer-related Fatigue
补充 Omega-3 治疗癌症相关疲劳的可行性
- 批准号:
8637297 - 财政年份:2014
- 资助金额:
$ 62.6万 - 项目类别:
Management of Cancer-Treatment-Induced Bone Loss
癌症治疗引起的骨质流失的管理
- 批准号:
8716700 - 财政年份:2013
- 资助金额:
$ 62.6万 - 项目类别:
Management of Cancer-Treatment-Induced Bone Loss
癌症治疗引起的骨质流失的管理
- 批准号:
9123535 - 财政年份:2013
- 资助金额:
$ 62.6万 - 项目类别:
Management of Cancer-Treatment-Induced Bone Loss
癌症治疗引起的骨质流失的管理
- 批准号:
8508394 - 财政年份:2013
- 资助金额:
$ 62.6万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 62.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 62.6万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 62.6万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 62.6万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 62.6万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 62.6万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 62.6万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 62.6万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 62.6万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 62.6万 - 项目类别: